Yiming Biotech is a technology-driven oncology company focused on tumor immunotherapy and early domestic leadership in CD47-targeted drug research. The company operates proprietary platforms including a dual-function antibody platform, a tumor immune target analysis platform, and a tumor immune function analysis platform. Its pipeline centers on CD47 with seven programs, two IND approvals, and 13 core patents granted or pending. Lead candidates IMM01 (a SIRPα-Fc fusion) and IMM0306 (a CD47/CD20 mAb‑Trap) are in Phase I trials; IMM2510 (VEGFxPD‑L1 mAb‑Trap) is another clinical program. Yiming says it will use new funding to accelerate clinical trials for IMM01, IMM0306 and IMM2510 and to advance several preclinical mono‑ and bispecific antibody programs. The company was founded in June 2015 and is registered in Shanghai’s Zhangjiang High‑Tech Park.

Total raised

$25M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2020